Bijuva 1 mg/100 mg Soft gel capsules.
PDF Leaflet Revision Date: 06 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Hormone replacement therapy for postmenopausal women with intact uterus.
Dosage (summary)
1 capsule daily in the evening with food.
Onset of Action / Duration
Onset: weeks, Duration: varies.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not indicated during pregnancy or lactation.
Key Drug Interactions
- Anticonvulsants
- Rifampicin
- St John's Wort
- Lamotrigine
- Ciclosporin
Contraindications
- Hypersensitivity
- Breast cancer
- Endometrial cancer
- Undiagnosed bleeding
- Thromboembolic disorders
- Liver disease
Common side effects
- Breast tenderness
- Headache
- Nausea
- Pelvic pain
- Vaginal bleeding
Counselling Points
- Take daily without interruption
- Report any unusual bleeding
- Monitor for thromboembolic symptoms
- Avoid during pregnancy
Serious warnings
- Increased risk of breast and endometrial cancer
- Thromboembolic events
- Ischaemic stroke risk
Important Disclaimer
The Bijuva 1 mg/100 mg Soft gel capsules. professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
